211 related articles for article (PubMed ID: 20171439)
41. A novel two-stage treatment of lentigo maligna using ablative laser therapy followed by imiquimod.
de Vries K; Rellum R; Habets JM; Prens EP
Br J Dermatol; 2013 Jun; 168(6):1362-4. PubMed ID: 23252724
[No Abstract] [Full Text] [Related]
42. Reply to: A practical guide on the use of imiquimod cream to treat lentigo maligna.
Muir J; McCormack C; De'Ambrosis B; Brown H; Kennedy D; Louie B; Smithers BM
Australas J Dermatol; 2022 May; 63(2):e197-e198. PubMed ID: 35262178
[No Abstract] [Full Text] [Related]
43. Diagnosis of Amelanotic Lentigo Maligna by Using In vivo Reflectance Confocal Microscopy.
Alani A; Ramsay B; Ahmad K
Acta Derm Venereol; 2016 Mar; 96(3):406-7. PubMed ID: 26524567
[No Abstract] [Full Text] [Related]
44. Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type.
Swetter SM; Chen FW; Kim DD; Egbert BM
J Am Acad Dermatol; 2015 Jun; 72(6):1047-53. PubMed ID: 25791801
[TBL] [Abstract][Full Text] [Related]
45. Treatment of lentigo maligna with imiquimod before staged excision.
Cotter MA; McKenna JK; Bowen GM
Dermatol Surg; 2008 Feb; 34(2):147-51. PubMed ID: 18093206
[TBL] [Abstract][Full Text] [Related]
46. [Lentigo maligna treated with 5% imiquimod cream].
Martín T; Ojeda A; Martínez S; Vera A
Actas Dermosifiliogr; 2005 Dec; 96(10):700-2. PubMed ID: 16476324
[TBL] [Abstract][Full Text] [Related]
47. Imiquimod in the treatment of lentigo maligna.
Rajpar SF; Marsden JR
Br J Dermatol; 2006 Oct; 155(4):653-6. PubMed ID: 16965411
[TBL] [Abstract][Full Text] [Related]
48. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod.
Wolf IH; Cerroni L; Kodama K; Kerl H
Arch Dermatol; 2005 Apr; 141(4):510-4. PubMed ID: 15837872
[TBL] [Abstract][Full Text] [Related]
49. Topical imiquimod therapy for lentigo maligna.
Mahoney MH; Joseph MG; Temple C
Ann Plast Surg; 2008 Oct; 61(4):419-24. PubMed ID: 18812714
[TBL] [Abstract][Full Text] [Related]
50. Topical imiquimod immunotherapy in the management of lentigo maligna.
Powell AM; Russell-Jones R; Barlow RJ
Clin Exp Dermatol; 2004 Jan; 29(1):15-21. PubMed ID: 14723712
[TBL] [Abstract][Full Text] [Related]
51. Prognostic markers in lentigo maligna patients treated with imiquimod cream: A long-term follow-up study.
Gautschi M; Oberholzer PA; Baumgartner M; Gadaldi K; Yawalkar N; Hunger RE
J Am Acad Dermatol; 2016 Jan; 74(1):81-87.e1. PubMed ID: 26601565
[TBL] [Abstract][Full Text] [Related]
52. Real-world experience of off-label use of imiquimod 5% as an adjuvant therapy after surgery or as a monotherapy for lentigo maligna.
Lallas A; Moscarella E; Kittler H; Longo C; Thomas L; Zalaudek I; Kyrgidis A; Manoli SM; di Meo N; Papageorgiou C; Apalla Z; Argenziano G
Br J Dermatol; 2021 Sep; 185(3):675-677. PubMed ID: 33894006
[No Abstract] [Full Text] [Related]
53. Imiquimod as an antiaging agent.
Metcalf S; Crowson AN; Naylor M; Haque R; Cornelison R
J Am Acad Dermatol; 2007 Mar; 56(3):422-5. PubMed ID: 17184874
[TBL] [Abstract][Full Text] [Related]
54. Treatment of lentigo maligna with topical 1% cidofovir.
Calista D
Br J Dermatol; 2007 Aug; 157(2):421-3. PubMed ID: 17596162
[No Abstract] [Full Text] [Related]
55. Recurrent lentigo maligna melanoma: regression associated with local azelaic acid 20%.
Vereecken P; Heenen M
Int J Clin Pract; 2002; 56(1):68-9. PubMed ID: 11831841
[TBL] [Abstract][Full Text] [Related]
56. A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions.
Hyde MA; Hadley ML; Tristani-Firouzi P; Goldgar D; Bowen GM
Arch Dermatol; 2012 May; 148(5):592-6. PubMed ID: 22431716
[TBL] [Abstract][Full Text] [Related]
57. Imiquimod for superficial and in situ skin malignancy.
Drug Ther Bull; 2009 Oct; 47(10):113-6. PubMed ID: 19809085
[TBL] [Abstract][Full Text] [Related]
58. Ocular effects of imiquimod with treatment of eyelid melanoma in situ.
Murchison AP; Washington CV; Soloman AR; Bernardino CR
Dermatol Surg; 2007 Sep; 33(9):1136-8. PubMed ID: 17760609
[No Abstract] [Full Text] [Related]
59. Efficacy of imiquimod 3.75% cream for the treatment of solar lentigo.
Cantisani C; Cantoresi F; Mercuri SR; Binic I; Golubovic M; Marino R; Paolino G
Dermatol Ther; 2020 Mar; 33(2):e13256. PubMed ID: 32031733
[No Abstract] [Full Text] [Related]
60. Treatment of periocular lentigo maligna with topical 5% Imiquimod: a review.
Neumann I; Patalay R; Kaushik M; Timlin H; Daniel C
Eye (Lond); 2023 Feb; 37(3):408-414. PubMed ID: 35835989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
